Cellular Therapy for Fanconi Anemia: The Past, Present, and Future

被引:16
|
作者
MacMillan, Margaret L. [1 ]
Hughes, Mark R. [2 ]
Agarwal, Suneet [3 ,4 ,5 ,6 ,7 ]
Daley, George Q. [3 ,4 ,5 ,6 ,7 ]
机构
[1] Univ Minnesota, Dept Pediat, Div Pediat Hematol Oncol & Blood & Marrow Transpl, Blood & Marrow Transplant Program, Minneapolis, MN 55455 USA
[2] Appl Genom Technol Ctr Michigan, Genesis Genet Inst, Detroit, MI USA
[3] Childrens Hosp Boston, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Stem Cell Transplantat Program,Div Pediat Hematol, Boston, MA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
[7] Harvard Stem Cell Inst, Boston, MA USA
关键词
BONE-MARROW-TRANSPLANTATION; PLURIPOTENT STEM-CELLS; APLASTIC-ANEMIA; DONORS; CYCLOPHOSPHAMIDE; IRRADIATION; DISEASE; BLOOD; ENGRAFTMENT; GENERATION;
D O I
10.1016/j.bbmt.2010.11.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Allogeneic hematopoietic cell transplantation (HCT) remains the only proven curative therapy for the hematologic manifestation of Fanconi anemia (FA). Over the past 2 decades, major advances have been made such that transplant outcomes have markedly improved. With the development of in vitro fertilization and preimplantation genetic diagnosis, HLA-matched sibling donor umbilical blood transplantation may be an option for more patients with FA. Recently, the use of pluripotent stem cells has been explored as a novel approach to model the hematopoietic developmental defects in FA, and to provide a potential source of autologous stem cells that can be genetically manipulated and used to generate corrected hematopoietic progenitors. Biol Blood Marrow Transplant 17: S109-S114 (2011) (C) 2011 American Society for Blood and Marrow Transplantation
引用
收藏
页码:S109 / S114
页数:6
相关论文
共 50 条
  • [21] Modern management of Fanconi anemia
    Dufour, Carlo
    Pierri, Filomena
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2022, (01) : 649 - 657
  • [22] Fanconi Anemia
    Green, Allison M.
    Kupfer, Gary M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (02) : 193 - +
  • [23] Endothelial cell direct reprogramming: Past, present, and future
    Cho, Seonggeon
    Aakash, Parthasarathy
    Lee, Sangho
    Yoon, Young-sup
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2023, 180 : 22 - 32
  • [24] Neuroscience in Nigeria: the past, the present and the future
    Balogun, Wasiu Gbolahan
    Cobham, Ansa Emmanuel
    Amin, Abdulbasit
    METABOLIC BRAIN DISEASE, 2018, 33 (02) : 359 - 368
  • [25] Wheat Blast: Past, Present, and Future
    Ceresini, Paulo Cezar
    Castroagudin, Vanina Lilian
    Rodrigues, Fabricio Avila
    Rios, Jonas Alberto
    Aucique-Perez, Carlos Eduardo
    Moreira, Silvino Intra
    Alves, Eduardo
    Croll, Daniel
    Nunes Maciel, Joao Leodato
    ANNUAL REVIEW OF PHYTOPATHOLOGY, VOL 56, 2018, 56 : 427 - 456
  • [26] Ferroptosis inhibitors: past, present and future
    Zhang, Lei
    Luo, Yi Lin
    Xiang, Yang
    Bai, Xin Yue
    Qiang, Rong Rong
    Zhang, Xin
    Yang, Yan Ling
    Liu, Xiao Long
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [27] The past, present and future of pulmonary rehabilitation
    Troosters, Thierry
    Blondeel, Astrid
    Janssens, Wim
    Demeyer, Heleen
    RESPIROLOGY, 2019, 24 (09) : 830 - 837
  • [28] Organic Nitrates: Past, Present and Future
    Franca-Silva, Maria S.
    Balarini, Camille M.
    Cruz, Josiane C.
    Khan, Barkat A.
    Rampelotto, Pabulo H.
    Braga, Valdir A.
    MOLECULES, 2014, 19 (09) : 15314 - 15323
  • [29] The past, present and future of anticholinergic drugs
    Healy, David
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2023, 13
  • [30] Bronchopulmonary Dysplasia: Past, Present and Future
    Philip, A. G. S.
    NEONATOLOGY, 2014, 106 (03) : 272 - 273